Loading
Radiation Therapy and Dosimetry / DNA Repair Mechanisms · Journal article
Frontiers in Oncology · August 14, 2026
Encouraging direction, but not yet definitive.
This is an in vitro mechanistic study in 3D uveal melanoma spheroids showing that inhibition of ATM, ATR, or DNA-PK protein kinases suppresses growth when combined with X-ray or proton beam radiation. The effect appears driven by persistent DNA double-strand breaks and chromosomal aberrations. The work is promising as proof-of-concept but lacks in vivo validation, human data, and quantified effect sizes needed to guide clinical translation.
In vitro experimental study using 3D spheroid models. 3D uveal melanoma spheroid models; no human subject enrollment or clinical setting. Intervention: Inhibition of ATM (AZD1390), ATR (AZD6738), and DNA-PK (AZD7648) combined with X-ray or proton beam therapy. Compared with: Radiation alone (X-rays or proton beam therapy without kinase inhibitors, implied but not explicitly detailed).
Inhibition of ATM (AZD1390), ATR (AZD6738), or DNA-PK (AZD7648) significantly suppresses UM spheroid growth when exposed to X-rays or proton beam therapy Suppression is primarily driven by delayed and persistent DNA double-strand breaks and chromosomal aberration accumulation Effect demonstrated in both X-ray and proton beam modalities tested
No information on inhibitor toxicity, off-target effects, or optimal dosing schedules
If confirmed in vivo and clinically, combining DNA damage response inhibitors with proton therapy could enhance treatment efficacy and potentially reduce radiation dose requirements in uveal melanoma. This remains preclinical evidence and does not yet support clinical application.
Sound experimental study in 3D models demonstrating that DNA damage response inhibitors enhance radiosensitivity to both X-rays and proton therapy, but limited to in vitro spheroids without clinical validation or human data.
As stated by the source record.
If confirmed in vivo and clinically, combining DNA damage response inhibitors with proton therapy could enhance treatment efficacy and potentially reduce radiation dose requirements in uveal melanoma. This remains preclinical evidence and does not yet support clinical application.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Introduction Proton beam therapy (PBT) is a well-established treatment modality for uveal melanoma (UM), where it exerts its therapeutic effect primarily through the induction of significant DNA damage, particularly DNA double strand breaks (DSBs) that are the most challenging for the cell to repair. Following DSB induction, a coordinated repair response is orchestrated by the key protein kinases, ataxia telangiectasia mutated (ATM), ataxia telangiectasia and Rad3-related (ATR) and DNA-dependent protein kinase catalytic subunit (DNA-PK). These enzymes detect damage and activate the appropriate DSB repair pathways, namely homologous recombination or non-homologous end joining to maintain genomic integrity. Targeting these major DNA damage response kinases is a promising therapeutic target in cancers, including UM, to enhance the therapeutic effect of radiation and potentially reduce the radiation dosage required for treatment, thus reducing the frequency and severity of adverse effects. Methods Here, we investigate the response of 3D spheroid models of UM to both X-rays and PBT in the presence of inhibitors of ATM (AZD1390), ATR (AZD6738) and DNA-PK (AZD7648). Results We demonstrate that inhibition of these protein kinases significantly suppresses the growth of UM spheroids exposed to both X-rays and PBT, which is primarily driven by delayed and persistent DSBs, leading to the accumulation of chromosomal aberrations. Discussion These results highlight the potential of combining ATM, ATR or DNA-PK inhibitors to enhance radiotherapy efficacy, and particularly with targeted PBT, to help improve clinical outcomes in UM.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.